Study: NCT00338377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Immunization
Description: 1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Immunization
Description: 1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Immunization
Description: 1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cells
Description: On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cells
Description: On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cells
Description: On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cells
Description: On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal T-Cells
Description: 5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal Interleukin-2
Description: 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.